DigiCon

@if (isset(session()->get('doctor')['vCentralCode']))

Back

@else

@endif

Q1 : What % of patients in your practice suffer from GERD? *

a) <10 b) 10-25 c) 25-40 d) >40

Q2 : In how many % patients suffering from GERD, do you prescribe a PPI as first line therapy? *

a) <25 b) 25-50 c) 50-75 d) 75-100

Q3 : What is the average duration of therapy in your patients? *

a) 4 weeks b) 8 weeks c) 12 weeks d) > 3 months

Q4 : Which one of the following factor you consider while prescribing PPIs as the most important factor?
a) Drug-drug interactions b) Relative efficacy c) Long term use safety d) Food-drug interaction

Q5 : If standard dose PPI does not give satisfactory results, the next step would be? *

a) BID dose

b) Switching to another PPI

c) PPI plus Prokinetic

d) Addition of other antacid medication

e) Dual release formulation

Q6 : If you have to use PPI+Prokinetic, your preference would be ?*
a) PPI+ Domperidone b) PPI+Levosulpiride c) PPI+Itopride d) PPI+ cinitapride

Q7 : What is the approximate duration of PPI+Prokinetic therapy? *
a) 4 weeks b) 8 weeks c) 12 weeks d) > 3 months

Q8 : Do co-morbidities have an impact on your choice of PPI? *
a) Yes b) No

If Yes, the co-morbidities would be

a) Hypertension b) Diabetes c) Asthma/COPD d) Renal disorders e) Cardiovascular comorbidities

Q9 : Do age & gender impact your choice of PPI? *
a) Yes b) No

If Yes,

a) Male b) <50 years age c) >50 years age

a) Female b) <50 years age c) >50 years age

Q10 : Do BMI impact the choice of PPI? *
a) Yes b) No

If Yes,

a) <25 b) 25-30 c) >30

Q11 : What are commonly reported side effects by patients? *

Q12 : How you rate the tolerability of Sompraz D in GERD patients management ?*

a) 1 - Very good

b) 2 - Good

c) 3 - Somewhat good

d) 4 - Somewhat bad

e) 5 - Bad

f) 6 - very bad

Q13 : In which type of patients Sompraz-D is preferred? *
a) Patients who do not respond to standard dose of PPI b) Patients who do not respond to double dose of PPI c) GERD patients with nausea and vomiting d) Any other

If any other, please specify

Q14 : Based on your experience how you rate the efficacy of Sompraz-D? *

a) 1 - Very good

b) 2 - Good

c) 3 - Somewhat good

d) 4 - Somewhat bad

e) 5 - Bad

f) 6 - very bad

Q15 : How commonly follow-up is done in patients of GERD who are on PPI-plus prokinetic combination? *
a) every weekly b) fortnightly c) At the end of month d) At the end of 2months

Q16 : In GERD treatment, what are the lifestyle modifications you suggest to your patients? * (you can tick multiple options)
a) Lose excess weight b) Eat smaller meals c) Don't eat two to three hours before bedtime d) Raise the head of your bed e) Increase the intake of protein

Q17 : Do you use PPI as maintainance therapy post intial management period? *
a) Yes b) No

if yes then what is the duration?

a) 3 months b) 6 months c) 9 months d) 12 months

Q18 : Is there any specific subgroup of patients where you prefere high dose PPI as preffered therapy? (you can tick multiple options)*

a) GERD with hiatus hernia

b) GERD patients with extraesophageal symptoms

c) Refractory GERD patients

d) Obese GERD patients

Q19 : What percentage of your patients gets extraesophageal symptoms of GERD? *

a) 5%

b) 5-10%

c) 10-20%

d) >20%

Q20 : What percentage of your patients suffer from hiatus hernia as complication of GERD? *

a) 5%

b) 5-10%

c) 10-20%

d) >20%

{{ $ActivityTypeName }}

Real world evidence survey to assess the GERD patient management and usage of Sompraz-D in the treatment of GERD